MedTrace Logo

Left Ventricular Fibrosis in Chronic Kidney Disease

NCT03176862 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2017-06-06

No results posted yet for this study

Summary

This study aims to understand the onset an functional consequences of left ventricular interstitial fibrosis in patients with chronic kidney disease (stage 2 to 5), as well as assess whether transplantation results in a regression of cardiac fibrosis.Thus all patients will undergo: 1) a cardiac magnetic resonance imaging (MRI) scan to assess cardiac function and measure left ventricular interstitial fibrosis; 2) a cardiopulmonary stress echocardiogram to understand the functional consequences of fibrosis and rule out any underlying ischaemic heart disease; 3) a 24 hour holter monitor and electrocardiogram (ECG) to assess whether these patients are at higher risk of arrhythmia.

Conditions

  • Chronic Kidney Diseases
  • Cardio-Renal Syndrome
  • Myocardial Fibrosis
  • Uraemic Cardiomyopathy

Interventions

DIAGNOSTIC_TEST

cardiac magnetic resonance scan

An MRI scan of the heart

DIAGNOSTIC_TEST

Cardiopulmonary exercise test with stress echocardiogram

An exercise bicycle test with echocardiogram done during the exercise.

DIAGNOSTIC_TEST

24-hour ECG holter monitor

3 stickers attached to a small monitor are worn for 24 hours.

DIAGNOSTIC_TEST

12-lead ECG

Can be done immediately by the bedside.

DIAGNOSTIC_TEST

Cardiopulmonary exercise test

An exercise bicycle test. No stress echocardiogram.

BIOLOGICAL

Blood test

20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.

Sponsors & Collaborators

  • British Heart Foundation

    collaborator OTHER

  • Dr Manvir Kaur Hayer

    lead OTHER

Principal Investigators

  • Nicola C Edwards, PhD · University Hospital Birmingham NHS Foundation Trust

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-07-31
Completion
2018-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03176862 on ClinicalTrials.gov